Dr. John Douglass, PhD, is first author and Dr. Joshua Thaler, MD, PhD is senior author on the article entitled “Astrocyte IKKβ/NF-κB signaling is required for diet-induced obesity and hypothalamic inflammation”, in press at Molecular Metabolism. The article reports the the first direct evidence that astrocyte-mediated inflammation promotes susceptibility to weight gain from high-fat diet feeding, suggesting a nonneuronal CNS cellular target for obesity therapeutics.
Dr. Mauricio Dorfman, PhD, is first author and Dr. Joshua Thaler, MD, PhD is senior author on the article entitled “Deletion of Protein Kinase C Lambda in POMC Neurons Predisposes to Diet-Induced Obesity”, published in the January 2017 issue of Diabetes. The article reports that reduced signaling by atypical protein kinase C lambda in POMC neurons lowers leptin responsiveness and melanocortin content, resulting in increased predisposition to diet-induced obesity. Other UW Diabetes Institute investigators co-authoring the paper include Gregory Morton, PhD and Michael Schwartz, MD.
Michael Schwartz, MD, presented a lecture entitled “Brain control of blood sugar and the future of diabetes treatment” at the UW Department of Medicine Grand Rounds on April 28, 2016. Click here to view the full lecture. Dr. Schwartz is the RH Williams Endowed Chair in Medicine, Professor, Division of Metabolism, Endocrinology and Nutrition, Director, UW Nutrition Obesity Research Center.
Dr. Chang Yeop Han, PhD, is first author and Dr. Alan Chait, MD, is senior author on the article article entitled “Serum amyloid A impairs the anti-inflammatory properties of HDL”, published in the December 2015 issue of The Journal of Clinical Investigation. The article reports findings indicating that inflammation results in a loss of the antiinflammatory properties of HDL on adipocytes, which appears to partially result from the SAA component of HDL binding to cell-surface proteoglycans, thereby preventing access of HDL to the plasma membrane. Other UW Diabetes Institute investigators co-authoring the paper include Chongren Tang, PhD, Baohai Shao, PhD, Savitha Subramanian, MD, Tomas Vaisar, PhD and William Osborne, PhD.
DOCE Director Michael Schwartz, MD and Novo Nordisk collaborate on exploring the role of the brain in regulating blood glucose and obesity
Dr. Michael Schwartz is collaborating with Novo Nordisk on a three-year project to explore the role of the brain in regulating blood glucose and obesity. The collaboration aims to understand factors mediating brain control of blood glucose and appetite with the ultimate goal of developing new therapeutic agents for the treatment of diabetes and obesity. The research will be conducted at UW Medicine’s South Lake Union research campus in Seattle, Washington and at Novo Nordisk’s research facilities in Måløv, Denmark. Over the next three years, Dr. Schwartz and his team together with Novo Nordisk researchers will conduct a research program on the effect of known hormonal factors working in the brain to regulate whole body glucose metabolism and appetite. Dr. Schwartz is the Robert H. Williams Endowed Chair in Medicine, Professor, Division of Metabolism, Endocrinology and Nutrition.
Read the full press release here
Dr. Michael Schwartz was featured in a recent Sigma Nutrition.com podcast: SNR #89: Dr. Michael Schwartz – Role of the Brain in Obesity, Insulin Resistance and Type 2 Diabetes Pathogenesis. Click this link to access the full episode.
Dr. Bornfeldt has been awarded a new R01 from the NIH/NHLBI for her project entitled Obesity and Arterial Metabolism. The overall hypothesis is that expression of the glucose transporter GLUT1 is of critical importance for the obesity-induced arterial metabolic signature, smooth muscle cell phenotype, and obesity-accelerated atherosclerosis. Dr. Bornfeldt is a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition, Professor of Pathology and the Deputy Director of the Diabetes Research Center.
NHLBI Renews Cardiovascular Disease and Diabetes Program Project (PI: Karin Bornfeldt, DOCE Associate Director)
The Cardiovascular Disease and Diabetes Program Project was recently renewed for five years, receiving a total of $11.8 million from the National Heart, Lung, and Blood Institute. The focus of the program project is to investigate whether diabetes causes high-density lipoprotein to lose its cardioprotective effects and whether this contributes to the increased cardiovascular disease risk associated with diabetes. This long-standing program project was originally awarded in 1958 with Robert H. Williams as PI. Edwin L. Bierman became PI in 1975, and Alan Chait served as PI from 1995 to 2013. Karin Bornfeldt became PI in 2013. The program includes four projects and three core units. Project Leaders are Jay Heinecke, Alan Chait and Karin Bornfeldt (DOCE), and Ira Goldberg and Edward Fisher, New York University. Core directors are Karin Bornfeldt, Tomas Vaisar (DOCE) and Kevin O’Brien (UW Medicine).
Drs. Wang Wang and Ian Sweet have been awarded an American Diabetes Association Innovative Award for their project entitled ‘Source and sites of action of hydrogen peroxide in mitochondria and cytosol of pancreatic islets’. The generation of hydrogen peroxide by the islet is associated with both the stimulation of insulin secretion and destruction of islet cells. Therefore, understanding the factors that control its production and action is critical for understanding how diabetes develops and how to treat the disease. The American Diabetes Association plays an important role in funding innovative pilot projects that generate proof of concept data. Dr. Sweet is an Associate Research Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition. Dr. Wang is an Assistant Professor of Anesthesiology and Pain Medicine.
Dr. Ian Sweet has been awarded an NIH Small Business Technology Transfer (STTR) award for his project entitled ‘Continuous measurement of cell growth as an optimal tool in drug toxicity testing’. The NIH STTR program allows US-owned and operated small businesses to engage in federal research and development (R&D) that has a strong potential for commercialization. Dr. Sweet’s project aims to develop a systematic and ultra-sensitive in vitro approach for measuring drug toxicity. Dr. Sweet is an Associate Research Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition.